Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Prior treatment

• Patients who are intolerant to systemic chemotherapy or surgery;
• Excessive tissue necrosis after conversion therapy, making it impossible to sample according to testing requirements
• Patients who have not undergone surgery after conversion therapy, only receiving radiofrequency ablation or chemotherapy follow-up
• Not all metastatic lesions were resected after conversion therapy, or liver metastatic lesions did not achieve R0 resection

Other

• Patients with multiple primary lesions;
• Blood samples and/or baseline tissue samples that do not meet the requirements for testing (hemolysis, low tumor cell content, insufficient DNA extraction yield, etc.);
• No definite mutations detected in the tissue, or mutations detected in tumor tissue were not covered by the designed small panel.

• Before implementing any trial-related procedures, written informed consent should be signed;
• \>=20 and \<= 85 years old, male or female;
• Patients with liver metastases pathologically confirmed as colorectal adenocarcinoma;
• According to the Response Evaluation Criteria for Solid Tumors (RECIST version 1.1), there is at least one lesion that can be measured by imaging;
• The multidisciplinary team (MDT) confirmed that the liver metastases were initially resectable ,without locally treatable extrahepatic metastases;
• The general physical condition is good (ECOG score 0-1);
• Life expectancy of more than 3 months;
• There is no obvious symptoms of primary bleeding, obstruction and other indications for emergency surgery;
• adequate organ function;
• samples meet NGS quality control requirements;
• The subjects are able and willing to comply with the visits, treatment plans, laboratory tests and other research-related procedures stipulated in the research protocol.